A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease (BeyoND)

• ClinicalTrials.gov Identifier: NCT02726386
• Recruitment Status: Active, not recruiting
• First Posted: April 1, 2016
• Results First Posted: May 6, 2023
• Last Update Posted: January 19, 2024
• Sponsor: NeuroDerm Ltd.
• Information provided by (Responsible Party): NeuroDerm Ltd.

Study Description

Brief Summary:

This is a multi-center, international, open-label, safety study of ND0612, a solution of levodopa/carbidopa (LD/CD) delivered via a pump system as a continuous SC infusion in subjects with advanced Parkinson's Disease (PD).

Condition or disease	Intervention/treatment	Phase
Parkinson's Disease	Drug: ND0612	Phase 2

Detailed Description:

This is a multi-center, international, open-label, safety study of ND0612, a solution of LD/CD delivered via a pump system as a continuous SC infusion in subjects with advanced PD. Two cohorts of subjects are candidates for this study: subjects who completed treatment in study ND0612H-006 within one month prior to enrollment (Cohort 1) and ND0612 naïve subjects or subjects who completed treatment in a ND0612 clinical study more than one month before screening (Cohort 2). After screening procedures and confirmation of the inclusion/exclusion criteria, subjects and their study partners will be trained and assisted at their homes during the first week of treatment on the proper operation of the pump system. One mandatory home visit will be performed during the first week and then on a monthly basis during 12-months of treatment. Subjects will return for in-clinic visits at Week 1 and at Months 1, 2, 3, 4, 6, 9, and 12 for assessment of safety and efficacy variables. Subjects will be allowed to continue with study treatment for an optional treatment extension period of up to Month 102 and the clinic visits will be performed every 3 months to assess subject long-term safety. Safety follow-up visits will occur 1, 2, and 3 months after the last SC infusion of ND0612 or after early termination.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 214 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Multicenter, International, Open-label, Safety Study of ND0612, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease
• Actual Study Start Date: May 4, 2016
• Actual Primary Completion Date: September 9, 2019
• Estimated Study Completion Date: February 2027

Arms and Interventions

Arm	Intervention/treatment
Experimental: 24-hour dosing regimen; Continuous SC infusion over 24 hours: fixed day rate of up to 0.64 mL/h for 18 hours, followed by a night rate of 0.08 mL/h for 6 hours to deliver a total daily dose of up to 720/90 mg of levodopa/carbidopa. All patients who had been previously assigned to the 24-hour group in the prior study continued on this dosing regimen; patients who had previously been assigned to the 14-hour daytime regimen were switched to the 24-hour regimen.	Drug: ND0612; ND0612, a solution of levodopa/carbidopa (LD/CD) delivered continuously subcutaneously (SC) via an infusion pump system; Other Name: ND0612H
Experimental: 16-hour dosing regimen; Continuous SC infusion for over 16 hours: fixed rate of 0.75 mL/h to deliver a total infusion dose of 720/90 mg of levodopa/carbidopa over 16 hours. The device is removed at night and patients in this group also receive a morning oral dose of levodopa/carbidopa upon awakening.	Drug: ND0612; ND0612, a solution of levodopa/carbidopa (LD/CD) delivered continuously subcutaneously (SC) via an infusion pump system; Other Name: ND0612H

Outcome Measures

Primary Outcome Measures :

1. Adverse Events (Long-term Safety) [ Time Frame: Baseline to Month 12 ]
   Long-term safety (systemic and local) assessment will be based on adverse events (AEs), with a focus on adverse events of special interest (AESI), i.e., infusion site reactions, cases of hypersensitivity, polyneuropathy.
2. Percentages of Subjects Who Complete the 12-month Treatment Period or Discontinue Due to AE (Tolerability) [ Time Frame: Baseline to Month 12 ]
   Tolerability will be assessed based on the percentage of subjects that complete the 12-month treatment period of the study and the percentage of subjects who discontinue from the 12-month treatment period due to an AE.

Secondary Outcome Measures :

1. Adverse Events (Long-term Safety) [ Time Frame: Month 12 to Month 102 ]
   Long-term safety (systemic and local) and tolerability will be based on AEs, with a focus on AESI, i.e., infusion site reactions, cases of hypersensitivity, polyneuropathy.

Other Outcome Measures:

1. Change of Daily "ON" Time Without Troublesome Dyskinesia [ Time Frame: Baseline to Month 12 ]
   Exploratory endpoint. "ON" time without troublesome dyskinesia is defined as the sum of "ON" time without dyskinesia and "ON" time with non-troublesome dyskinesia. Daily "ON" time without troublesome dyskinesia will be assessed based on home "ON/OFF" diaries and normalized to 16 hours of awake time.
2. Change of Daily "OFF" Time [ Time Frame: Baseline to Month 12 ]
   Exploratory endpoint. Daily "OFF" time will be assessed based on home "ON/OFF" diaries and normalized to 16 hours of awake time.
3. Change of Total Daily Dose of Oral LD/DDI [ Time Frame: Baseline to Month 12 ]
   Exploratory endpoint. Total daily dose of oral Levodopa (LD)/Dopa-Decarboxylase Inhibitor (DDI).
4. Proportion of Responders [ Time Frame: Baseline to Month 12 ]
   Exploratory endpoint. A responder is defined as a subject that experiences ≥50% reduction in "OFF" time from Baseline. Improvement of ≥50% in "OFF" time will be assessed based on home "ON/OFF" diaries and normalized to 16 hours of awake time.
5. Change of Daily "ON" Time With Troublesome Dyskinesia [ Time Frame: Baseline to Month 12 ]
   Exploratory endpoint. Daily "ON" time with troublesome dyskinesia will be assessed based on home "ON/OFF" diaries in a subset of subjects who had more than 1 hour of troublesome dyskinesia at baseline. It will be normalized to 16 hours of awake time.
6. Change of PDQ-39 Scores [ Time Frame: Baseline to Month 12 ]
   Exploratory endpoint. Quality of Life in Parkinson's Disease (PDQ)-39 is a 39-item, self-administered questionnaire with 8 discrete dimensions (mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort.). The PDQ-39 Summary Index is the sum of the dimension scores divided by the number of dimensions. Higher scores indicate a worse quality of life.
7. Change of EQ-5D-5L Scores [ Time Frame: Baseline to Month 12 ]
   Exploratory endpoint. The perception of general quality of life (QoL) will be rated by the subjects using the EuroQoL 5-dimensions 5-severity levels (EQ-5D-5L) questionnaire. The EQ-5D-5L consists of 2 pages, the EQ-5D-5L descriptive system and the EQ Visual Analogue Scale (VAS). The descriptive system comprises 5 dimensions (mobility, self care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The EQ VAS records the respondent's self-rated health on a 20 cm vertical VAS with endpoints labelled 'the best health you can imagine' and 'the worst health you can imagine'. Decrease in the 5-dimensions scores and increase in EQ VAS score will indicate improvement.
8. Change of UPDRS Part II (ADL) [ Time Frame: Baseline to Month 12 ]
   Exploratory endpoint. The Unified Parkinson's disease rating scale (UPDRS) is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS Part II (activity of daily living) score was calculated as the sum of the individual UPDRS items 5-17. The Part II score is the sum of the answers to the 13 questions that comprise Part II, each of which are measured on a 5-point scale (i.e., 0 is normal and 4 indicates a severe abnormality). Higher scores correlate with greater impairments for daily activities.
9. Change in CGI-Severity and CGI-Improvement [ Time Frame: Baseline to Month 12 ]
   Exploratory endpoint. Clinical Global Impression (CGI) Severity (CGI-S) and Improvement (CGI-I) are rated by the investigator or designee. CGI-S employs a 7-point scale with 1 being "not at all ill" and 7 being "among the most severely ill subjects" for severity rating. The CGI-I employs a 7-point scale with 1 being "very much improved" and 7 being "very much worse" for improvement rating.
10. Change in SGI-Improvement [ Time Frame: Baseline to Month 12 ]
    Exploratory endpoint. Subjects Global Impression of Improvement (SGI-I) is rated by the subject. The SGI-I employs a 7-point scale with 1 being "very much improved" and 7 being "very much worse" for improvement rating.
11. Change in PDSS-2 Total Score [ Time Frame: Baseline to Month 12 ]
    Exploratory endpoint. The quality of night sleep is rated by the subjects using the Parkinson's Disease Sleep Scale (PDSS)-2, which includes questions addressing 15 commonly reported symptoms associated with sleep disturbance in PD. Higher scores indicate a lower quality of sleep, i.e., a reduction in the score indicates an improvement in sleep quality.
12. Change in UPDRS Part III (Motor Score) [ Time Frame: Baseline to Month 12 ]
    Exploratory endpoint. The Unified Parkinson's Disease Rating Scale (UPDRS) is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. UPDRS part III (motor) score is calculated as the sum of the individual UPDRS items 18-31, each of which are measured on a 5-point scale (i.e., 0 is normal and 4 indicates a severe abnormality). Higher scores correlate with greater motor impairment.
13. Change in Percentage of "OFF" Time and Percentage of Good "ON" During the First 3 Hours Since the Subject is Awake After 06:00 (6 am) [ Time Frame: Baseline to Month 12 ]
    Exploratory endpoint. Good "ON" time (or "ON" time without troublesome dyskinesia) is defined as the sum of "ON" time without dyskinesia and "ON" time with non-troublesome dyskinesia. For this endpoint, Good "ON" time and "OFF" time will be assessed based on home "ON/OFF" diaries during the first 3 hours since the subject is awake after 06:00 (6 am).
14. Change in ND0612 Total Dose [ Time Frame: Baseline to Month 12 ]
    Exploratory endpoint. Change in ND0612 total daily dose.
15. Proportion of Patients Who Reduced ND0612 Total Dose [ Time Frame: Baseline to Month 102 ]
    Exploratory endpoint. Proportion of patients who reduced ND0612 total dose at any time during the study.

Eligibility Criteria

• Ages Eligible for Study: 30 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

INCLUSION CRITERIA:

Cohort 1.

1. Subject is able to, and has signed an Institutional Review Board/Ethics Committee (IRB/EC)-approved informed consent form (ICF).
2. Subject has completed the treatment period of study ND0612H-006 not more than one month prior to enrolling in ND0612H-012.
3. Willing and able to administer the SC infusion alone or with the assistance of a study partner and able to comply with the study specific procedures.

Cohort 2.

1. Male and female PD subjects of any race aged at least 30 years who sign an IRB/EC-approved ICF.
2. PD diagnosis consistent with the UK Brain Bank Criteria.
3. Modified Hoehn & Yahr scale in "ON" state of stage ≤3.
4. Taking at least 4 doses/day of LD/DDI (or at least 3 doses/day of Rytary) and taking, or have attempted to take, at least one other PD treatment for at least 30 days.
5. Subjects must be stable on their anti-PD medications for at least 30 days before Day 1.
6. Subjects may have had prior exposure to SC apomorphine injections/infusion but must have stopped continuous apomorphine administration at least 4 weeks before the screening visit. Treatment with apomorphine is prohibited during the entire ND0612 treatment period.
7. Must have a minimum of 2 hrs of "OFF" time per day with predictable early morning "OFF" periods as estimated by the subject.
8. Must have predictable and well defined early morning "OFF" periods with a good response to LD for treatment of the early morning "OFF" in the judgement of the investigator.
9. Mini Mental State Examination (MMSE) score ≥26.
10. No clinically significant medical, psychiatric or laboratory abnormalities which the investigator judges would be unsafe or non-compliant in the study.
11. Female subjects must be surgically sterile (hysterectomy, bilateral oophorectomy, or tubal ligation), postmenopausal (defined as cessation of menses for at least 1 year), or willing to practice a highly effective method of contraception. All female participants must be non-lactating and non-pregnant and have a negative urine pregnancy test at Screening and at Baseline. Female subjects of childbearing potential must practice a highly effective method of contraception (e.g., oral contraceptives, intrauterine devices, partner with vasectomy), 1 month before enrollment, for the duration of the study, and 3 months after the last dose of study drug. Alternatively, true abstinence is acceptable when it is in line with the subject's preferred and usual lifestyle. If a subject is usually not sexually active but becomes active, the subject and sexual partner must comply with the contraceptive requirements detailed above.
12. Willing and able to administer the SC infusion alone or with the assistance of a study partner after a screening period of up to 40 days and willing and able to comply with study requirements.
13. Subjects should have a named study partner.

EXCLUSION CRITERIA:

Cohort 1 and 2. Previously unable to tolerate ND0612 and/or have experienced intolerable adverse drug reactions associated with its use, regardless of the dosing regimen administered.

Cohort 2.

1. Atypical or secondary parkinsonism.
2. Acute psychosis or hallucinations in past 6 months.
3. Any relevant medical, surgical, or psychiatric condition, laboratory value, or concomitant medication which, in the opinion of the Investigator makes the subject unsuitable for study entry or potentially unable to complete all aspects of the study.
4. Any malignancy in the 5 years prior to randomization (excluding basal cell carcinoma of the skin or cervical carcinoma in situ that have been successfully treated).
5. Positive serum serology for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or Human Immunodeficiency Virus (HIV) at the Screening visit.
6. Prior neurosurgical procedure for PD, or Duodopa treatment
7. Subjects with a history of drug abuse or alcoholism within the past 12 months.
8. Clinically significant ECG rhythm abnormalities.
9. Renal or liver dysfunction that may alter drug metabolism including: serum creatinine >1.3 mg/dL, serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2 x upper limit of normal (ULN), total serum bilirubin >2.5 mg/dL.
10. Current participation in a clinical trial with an investigational product or past participation within the last 30 days before Day 1.

Contacts and Locations

Locations

United States, Arizona

Xenoscience

Phoenix, Arizona, United States, 85004

United States, Arkansas

Clinical Trials Inc.

Little Rock, Arkansas, United States, 72205-6421

United States, California

The Parkinsons and Movement Disorder Institute

Fountain Valley, California, United States, 92708-5153

Neuro Pain Medical Center

Fresno, California, United States, 93710

United States, Colorado

University of Colorado Denver

Aurora, Colorado, United States, 80045

Rocky Mountain Movement Disorders Center

Englewood, Colorado, United States, 80113-2776

United States, Florida

Parkinson's Disease and Movement Disorder Center of Boca Raton

Boca Raton, Florida, United States, 33486-2359

MD Clinical

Hallandale Beach, Florida, United States, 33009

Infinity Clinical Research, LLC

Hollywood, Florida, United States, 33021

University of Florida Health at Jacksonville

Jacksonville, Florida, United States, 32209

Neurology Associates, PA

Maitland, Florida, United States, 32751-4723

Parkinsons Disease Treatment Center of Southwest Florida

Port Charlotte, Florida, United States, 33980

Suncoast Neuroscience Associates

Saint Petersburg, Florida, United States, 33713-8844

Infinity Clinical Research, LLC

Sunrise, Florida, United States, 33351

USF Health Parkinson's Disease and Movement Disorders

Tampa, Florida, United States, 33613

United States, Illinois

Northwestern University

Chicago, Illinois, United States, 60611

United States, Iowa

Unity Point Health

Des Moines, Iowa, United States, 50309

United States, Maryland

University of Maryland, Neurology

Baltimore, Maryland, United States, 21201

United States, Michigan

QUEST Research Institute

Farmington Hills, Michigan, United States, 48334

Henry Ford Hospital

West Bloomfield, Michigan, United States, 48322-3013

United States, New Jersey

Pyramid Clinical Research

Somerset, New Jersey, United States, 08873-3448

United States, Ohio

University of Cincinnati

Cincinnati, Ohio, United States, 45267

United States, Oklahoma

The Movement Disorder Clinic of Oklahoma

Tulsa, Oklahoma, United States, 74136

United States, Virginia

Synergy Trials

Richmond, Virginia, United States, 23226

Sentara Neuroscience Institute

Virginia Beach, Virginia, United States, 23456-0168

United States, Washington

Premier Research

Spokane, Washington, United States, 99202-1461

Austria

Medical University Innsbruck

Innsbruck, Austria, 6020

Czechia

NEUROHK, s.r.o.

Chocen, Czechia, 565 01

Clintrial s.r.o.

Praha, Czechia, 100 00

Vestra Clinics, s.r.o.

Rychnov nad Kněžnou, Czechia, 516 01

France

Centre Hospitalier d'Aix

Aix-en-Provence, France, 13616

CHU d'Amiens, Hopital Sud

Amiens Cedex 1, France, 80054

Hopital Neurologique Pierre Wertheimer

BRON Cedex, France, 69677

Hôpital Gabriel Montpied

Clermont-Ferrand Cedex 1, France, 63003

Hopital Roger Salengro

Lille Cedex, France, 59037

Hopital de la Timone

Marseille, France, 13385

CHU de Poitiers

Poitiers, France, 86021

Germany

Kliniken Beelitz GmbH

Beelitz-Heilstätten, Germany, 14547

St. Josefs Hospital

Bochum, Germany, 44791

Klinikum-Bremerhaven Reinkenheide

Bremerhaven, Germany, 27574

Universitaetsklinikum Carl Gustav Carus an der Technischen Universitaet Dresden

Dresden, Germany, 1307

Klinik Haag

Haag in Oberbayern, Germany, 83527

Universitaets-und Rehabilitationskliniken Ulm

Ulm, Germany, 89081

Israel

Barzilai MC

Ashkelon, Israel, 7830604

Hadassah Medical Center, Ein-Kerem Campus

Jerusalem, Israel, 91120

Rabin Medical Center

Petah Tikva, Israel, 49100

Chaim Sheba Medical Center

Ramat Gan, Israel, 56520

Sourasky Medical Center

Tel Aviv, Israel, 64239

Italy

University Foundation

Chieti, Italy, 66100

AOU Pisa

Pisa, Italy, 56126

IRCCS San Raffaele Pisana

Rome, Italy, 00163

IRCCS Hospital San Camillo Venice

Venice, Italy, 30126

Poland

Centrum Medyczne PLEJADY

Kraków, Poland, 30-363

Krakowska Akademia Neurologii Sp. z o.o.

Kraków, Poland, 31-505

Indywidualna Praktyka Lekarska prof. dr hab

Lublin, Poland, 20-016

Spain

Hospital Clinic de Barcelona

Barcelona, Spain, 08036

Hospital Universitario de la Princesa

Madrid, Spain, 28006

Sponsors and Collaborators

NeuroDerm Ltd.

Investigators

• Study Director: Laurence Salin, MD; NeuroDerm Ltd.

  Study Documents (Full-Text)

Documents provided by NeuroDerm Ltd.:

Study Protocol  [PDF] December 28, 2020

Statistical Analysis Plan  [PDF] August 27, 2019

More Information

Publications of Results:

Poewe W, Stocchi F, Arkadir D, Ebersbach G, Ellenbogen AL, Giladi N, Isaacson SH, Kieburtz K, LeWitt P, Olanow CW, Simuni T, Thomas A, Zlotogorski A, Adar L, Case R, Oren S, Fuchs Orenbach S, Rosenfeld O, Sasson N, Yardeni T, Espay AJ; BeyoND study group. Subcutaneous Levodopa Infusion for Parkinson's Disease: 1-Year Data from the Open-Label BeyoND Study. Mov Disord. 2021 Nov;36(11):2687-2692. doi: 10.1002/mds.28758. Epub 2021 Sep 8.

• Responsible Party: NeuroDerm Ltd.
• ClinicalTrials.gov Identifier: NCT02726386
• Other Study ID Numbers: ND0612H-012
• First Posted: April 1, 2016
• Results First Posted: May 6, 2023
• Last Update Posted: January 19, 2024
• Last Verified: January 2024

Additional relevant MeSH terms:

Parkinson Disease; Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases